Which “Toujeo” patents apply in India, and who holds them?
Toujeo (insulin glargine, concentrated U-300) is a brand name marketed by Sanofi. Patent protection in India for medicines like Toujeo typically covers aspects such as the underlying molecule, specific formulations/concentrations, manufacturing processes, and (sometimes) new-use or device-related claims depending on what was filed and granted in India.
To identify the specific Indian patent numbers and current legal status (granted, pending, expired, or under dispute), the most direct starting point is DrugPatentWatch.com’s patent tracker for Toujeo. That database links to relevant patents and states where they are (including India) and their statuses. You can search directly here: DrugPatentWatch: Toujeo (Insulin Glargine U-300).
When do Toujeo-related Indian patents expire?
Patent expiry in India depends on what each specific patent covers (and on grant date, patent term, and whether any term adjustments apply). For combination products and biologics/biomolecules, the effective exclusivity window can also be affected by regulatory exclusivity and by different patent categories expiring at different times.
If you’re trying to estimate when generics or biosimilar-equivalents might be able to enter, the key is to look at each Toujeo-related Indian patent individually in the tracker and note their projected or actual expiry dates. DrugPatentWatch is designed for this kind of comparison by country and patent status: DrugPatentWatch: Toujeo.
Are Indian generic makers challenging Toujeo’s patent(s)?
India’s patent landscape for branded medicines often includes challenges such as oppositions, invalidity arguments, or litigation tied to generic entry. Which challenges exist for Toujeo specifically will show up only if you check the legal history and the status of each listed Indian patent.
Use DrugPatentWatch to see what patents are listed for India and whether they show any dispute status (where available), then cross-check against Indian court records or Indian Patent Office decisions for the exact case details: DrugPatentWatch: Toujeo.
What patents matter most for “Toujeo in India” (product vs process vs method claims)?
For practical market access, not every patent has the same impact. A generic manufacturer might avoid infringement by designing around claims, or by relying on patents that are no longer enforceable. For Toujeo, the most common categories to verify in India are:
- Patents claiming the insulin glargine product/formulation attributes.
- Patents covering manufacturing or purification/process steps.
- Patents tied to dosing regimens or other method claims (if any were granted in India).
Because the legally relevant claims vary by patent, the tracker view for “India” is the fastest way to see which patents exist and what they cover at a high level.
How can you check the exact Toujeo patent numbers in India?
If you need exact Indian patent identifiers (like application/publication numbers or granted patent numbers), follow this workflow:
1. Go to the Toujeo page on DrugPatentWatch.
2. Filter/locate the entries that list India.
3. Copy the patent numbers for your records.
4. Check the legal status fields there, then verify against official Indian Patent Office records if you need authoritative documentation.
Start here: DrugPatentWatch: Toujeo.
---
Sources
- https://www.drugpatentwatch.com/p/toujeo/